Causes of early death and treatment‐related death in newly diagnosed pediatric acute myeloid leukemia: Recent experiences of the Dutch Childhood Oncology Group

Abstract

Background With the current more effective treatment regimens for pediatric acute myeloid leukemia (AML), research on early death (ED), treatment‐related mortality (TRM), and toxicity becomes increasingly important. The aim of this study was to give an overview of the frequency, clinical features, and risk factors associated with ED and TRM in first complete remission (CR1) during the last three consecutive treatment protocols of the Dutch Childhood Oncology Group (DCOG) between 1998 and 2014. Methods Incidence and risk factors associated with ED and TRM in CR1 were retrospectively studied in 245 patients treated according to the Dutch ANLL‐97/AML‐12 (n = 118), AML‐15 (n = 60), or DB AML‐01 (n = 67) protocols. Results The incidence of ED was, respectively, 5.1%, 6.7%, and 3.0% excluding deaths before treatment (P = NS), and 7.4%, 11.1%, and 4.4% including deaths before the onset of treatment. Severe underweight at initial diagnosis was significantly associated with more frequent ED. When relapse was included as a competing risk, cumulative incidence of death in CR1 were 5.9%, 5.0%, and 4.6% for ANLL97, AML15, and DB01, respectively (P = NS). The most important cause of TRM included infectious and SCT‐related complications. Conclusion We report relatively stable rates of ED and TRM in CR1 in the latest completed DCOG protocols for newly diagnosed AML patients. The most important causes of TRM were SCT‐ or infection‐related, warranting further evaluation and awareness.

Pediatric Acute Myeloid Leukemia in India: A Systematic Review

“…34 Similar to previous studies from India, the current review estimated a high incidence of induction mortality (12%) and overall TRM (23%), which is much higher compared with 5 to 10% occurring in HICs. 4 5 35 36 37 High rates of infection with multidrug-resistant organisms, invasive fungal infections, and poor nutritional status have led to poor tolerance and subsequently a high TRM during intensive chemotherapy. Uppuluri et al highlighted that early intervention by the pediatric intensive care team and granulocyte transfusion positively impacts survival.…”

Pediatric Acute Myeloid Leukemia—Past, Present, and Future

“…These must be considered acute emergencies and treated immediately in cooperation with an experienced pediatric oncology center. Effective, quality-assuring structures (central consultation, reference laboratories), as established in some European countries, improve the chances of survival [83].…”

Minimally myelosuppressive regimen for remission induction in pediatric AML: long-term results of an observational study

“…5 Progress in supportive care has reduced early death rates and overall treatment-related mortality (TRM). 6,7 However, concerns have been raised about the late effects of intensive chemotherapy in long-term survivors. 8 Moreover, despite the increasing intensity of chemotherapy, optimal supportive care, and unlimited access to HSCT, overall survival (OS) has stagnated at approximately 75% in high-income countries.…”